Sonoma Pharmaceuticals
SNOA
13 hedge funds and large institutions have $631K invested in Sonoma Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 11 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.26% more ownership
Funds ownership: 0.04% → 0.3% (+0.26%)
27% less capital invested
Capital invested by funds: $870K → $631K (-$239K)
41% less funds holding
Funds holding: 22 → 13 (-9)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$69.7K |
| 2 |
LWM
Liberty Wealth Management
Oakland,
California
|
+$32.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.7K |
| 4 |
BlackRock
New York
|
+$461 |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$154 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$73K |
| 2 |
VF
Virtu Financial
New York
|
-$67K |
| 3 |
Mercer Global Advisors
Denver,
Colorado
|
-$61K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$42K |
| 5 |
Goldman Sachs
New York
|
-$22K |
SNOA Hedge Fund Activity: Q2 2019 in Review
13 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2019, worth a combined $631K — down 27% from $870K a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SNOA and 2 opened new positions — a net loss of 9 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $69.7K. The largest seller was Vanguard Group, exiting entirely with an estimated $73K sold.
- 13 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2019, down from 22 in Q1 2019.
- Funds reported $631K of Sonoma Pharmaceuticals stock for Q2 2019, down 27% quarter-over-quarter.
- 2 funds opened new Sonoma Pharmaceuticals positions in Q2 2019 and 11 closed out, a net change of -9 holders.
- The largest Sonoma Pharmaceuticals buyer in Q2 2019 was Renaissance Technologies, an estimated $69.7K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2019 was Vanguard Group, an estimated $73K sold.
Based on aggregated 13F filings for Q2 2019.